Stocks & Financial News
Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts
Novanta Announces Financial Results for the First Quarter 2024
Financial Highlights Three Months Ended
--------------------------------------- ------------------------------------------------------------------------------------------------------------------------ --------------------
(In millions, except per share amounts) March 29, March 31,
2024 2023
---------------------------------------- -------------------- ---------------------------------------- --------------------
GAAP
Revenue $ 230.9 $ 219.1
Operating Income $ 25.6 $ 26.3
Net Income $ 14.7 $ 18.3
Diluted EPS $ 0.41 $ 0.51
Non-GAAP*
Adjusted Operating Income $ 40.1 $ 36.9
Adjusted Diluted EPS $ 0.74 $ 0.74
Adjusted EBITDA $ 49.7 $ 47.0
"Novanta achieved great results for the first quarter, beating expectations for sales, profit, and cash flow," said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. "We finished the quarter with $231 million in revenue, adjusted gross margin of 46.3%, adjusted EBITDA of $50 million, and more than doubling our operating cash flow year over year. In addition, we are pleased with our progress at integrating the recent Motion Solutions acquisition."
First Quarter
During the first quarter of 2024, Novanta generated GAAP revenue of $230.9 million, an increase of $11.8 million, or 5.4%, versus the first quarter of 2023. The Company's acquisition activities resulted in an increase in revenue of $21.2 million, or 9.7%, compared to the first quarter of 2023. Changes in foreign currency exchange rates year over year had immaterial impact on our revenue during the first quarter of 2024. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was a decrease of 4.2% for the first quarter of 2024 (see "Organic Revenue Growth" in the non-GAAP reconciliations below).
In the first quarter of 2024, GAAP operating income was $25.6 million, compared to $26.3 million in the first quarter of 2023. GAAP net income was $14.7 million in the first quarter of 2024, compared to $18.3 million in the first quarter of 2023. GAAP diluted earnings per share ("EPS") was $0.41 in the first quarter of 2024, compared to $0.51 in the first quarter of 2023.
Adjusted Diluted EPS was $0.74 in the first quarter of 2024, compared to $0.74 in the first quarter of 2023. Diluted weighted average shares outstanding was 36.1 million in the first quarter of 2024. Adjusted EBITDA was $49.7 million in the first quarter of 2024, compared to $47.0 million in the first quarter of 2023.
Operating cash flow for the first quarter of 2024 was $32.8 million, compared to $10.2 million for the first quarter of 2023.
Financial Guidance
For the second quarter of 2024, the Company expects GAAP revenue of approximately $230 million to $235 million. The Company expects Adjusted Gross Profit Margin to be approximately 46.0% to 46.3%. The Company expects Adjusted EBITDA to be in the range of $48 million to $50 million and Adjusted Diluted EPS to be in the range of $0.68 to $0.74. The Company's guidance assumes no significant changes in foreign exchange rates.
Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company's forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; future changes in the fair value of contingent considerations; future restructuring expenses; foreign exchange gains/(losses); significant discrete income tax expenses (benefits); benefits or expenses associated with the completion of tax audits; divestitures and related expenses; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; and other charges reflected in the Company's reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta's non-GAAP financial measures, see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
The Company will host a conference call on Tuesday, May 7, 2024 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company's website at www.novanta.com. The replay will remain available until Monday, July 1, 2024.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Operating Income, Adjusted Operating Margin, Adjusted Income Before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Net Income, and Net Debt.
The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management's belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company's day-to-day business in accordance with the execution of the Company's strategy. This strategy includes streamlining the Company's existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company's business through significant internal investments, and broadening the Company's product and service offerings through acquisitions of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company's overall financial performance and can adversely affect the comparability of its operating results and investors' ability to analyze the business from period to period.
The Company's Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used to determine bonus payments for senior management and employees. The Company has also used in the past, and may use in the future, Adjusted Diluted EPS and Adjusted EBITDA as performance targets for certain performance-based restricted stock units. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management's method of analysis.
Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.
Safe Harbor and Forward-Looking Information
Certain statements in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as "expect," "intend," "anticipate," "estimate," "believe," "future," "could," "should," "plan," "aim," and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the second quarter of 2024; expectations for our end markets and market position; our competitive position, including our positioning for long-term growth and other statements that are not historical facts.
These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers' businesses, capital expenditures and level of business activities; risks associated with epidemics, pandemics or other public health crises, such as the COVID-19 pandemic; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and other similar factors; disruptions or breaches in security of our or our third-party providers' information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors' products; disruptions in the supply of certain key components and other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations related to our business or products; actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements; our failure to implement new information technology systems successfully; changes in foreign currency rates; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate sustainability policies and practices; the effects of climate change and related regulatory responses; our exposure to the credit risk of some of our customers and in weakened markets; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.
Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company's operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company's beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.
About Novanta
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta's common shares are quoted on Nasdaq under the ticker symbol "NOVT."
More information about Novanta is available on the Company's website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars or shares, except per share amounts)
(Unaudited)
Three Months Ended
---------------------------------------------------------------------------------------------------- --------------------
March 29, March 31,
2024 2023
------------------------------ -------------------- ------------------------------ --------------------
Revenue $ 230,916 $ 219,126
Cost of revenue 130,500 121,498
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Gross profit 100,416 97,628
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Operating expenses:
23,246 22,828
Research and development and engineering
43,530 40,923
Selling, general and administrative
5,750 5,089
Amortization of purchased intangible assets
2,283 2,476
Restructuring, acquisition, and related costs
-------------------- ---------- -------------------- -------------------- ---------- --------------------
74,809 71,316
Total operating expenses
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Operating income 25,607 26,312
Interest income (expense), net (8,254 ) (6,332 )
Foreign exchange transaction gains (losses), net (321 ) (77 )
Other income (expense), net (116 ) (166 )
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Income before income taxes 16,916 19,737
Income tax provision (benefit) 2,240 1,472
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Net Income $ 14,676 $ 18,265
==================== ========== ==================== ==================== ========== ====================
Earnings per common share:
$ 0.41 $ 0.51
Basic
$ 0.41 $ 0.51
Diluted
Weighted average common shares outstanding--basic 35,914 35,810
NOVANTA INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars)
(Unaudited)
March 29, December 31,
2024 2023
------------------------------ -------------------- ------------------------------ --------------------
ASSETS
Current Assets
$ 93,520 $ 105,051
Cash and cash equivalents
150,911 139,410
Accounts receivable, net
161,371 149,371
Inventories
23,014 21,465
Prepaid expenses and other current assets
-------------------- ---------- -------------------- -------------------- ---------- --------------------
428,816 415,297
Total current assets
Property, plant and equipment, net 113,461 109,449
Operating lease assets 44,649 38,302
Intangible assets, net 215,090 145,022
Goodwill 589,856 484,507
Other assets 18,720 33,479
-------------------- ---------- -------------------- -------------------- ---------- --------------------
$ 1,410,592 $ 1,226,056
Total assets
==================== ========== ==================== ==================== ========== ====================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
$ 4,847 $ 4,968
Current portion of long-term debt
71,401 57,195
Accounts payable
75,158 77,012
Accrued expenses and other current liabilities
-------------------- ---------- -------------------- -------------------- ---------- --------------------
151,406 139,175
Total current liabilities
Long-term debt 508,858 349,404
Operating lease liabilities 42,926 37,345
Other long-term liabilities 25,687 26,672
-------------------- ---------- -------------------- -------------------- ---------- --------------------
728,877 552,596
Total liabilities
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Stockholders' Equity:
681,715 673,460
Total stockholders' equity
-------------------- ---------- -------------------- -------------------- ---------- --------------------
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of U.S. dollars)
(Unaudited)
Three Months Ended
-------------------------------------------------------------------------------------------------------- --------------------
March 29, March 31,
2024 2023
------------------------------ -------------------- ---------------------------------- --------------------
Cash flows from operating activities:
Net Income $ 14,676 $ 18,265
Adjustments to reconcile net income to net cash provided by operating activities:
12,929 11,731
Depreciation and amortization
6,077 6,466
Share-based compensation
(3,711 ) (3,695 )
Deferred income taxes
4,513 2,587
Other
Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions:
(4,162 ) (2,920 )
Accounts receivable
(3,781 ) 52
Inventories
6,288 (22,241 )
Other operating assets and liabilities
-------------------- ---------- -------------------- -------------------- -------------- --------------------
Net cash provided by (used in) operating activities 32,829 10,245
-------------------- ---------- -------------------- -------------------- -------------- --------------------
Cash flows from investing activities:
(191,200 ) --
Cash paid for business acquisition, net of working capital adjustments
(6,415 ) (3,620 )
Purchases of property, plant and equipment
-------------------- ---------- -------------------- -------------------- -------------- --------------------
Net cash provided by (used in) investing activities (197,615 ) (3,620 )
-------------------- ---------- -------------------- -------------------- -------------- --------------------
Cash flows from financing activities:
198,000 --
Borrowings under revolving credit facilities
(35,976 ) (15,309 )
Repayments under term loan and revolving credit facilities
(8,385 ) (9,601 )
Payments of withholding taxes from share-based awards
(176 ) (156 )
Other financing activities
-------------------- ---------- -------------------- -------------------- -------------- --------------------
Net cash provided by (used in) financing activities 153,463 (25,066 )
-------------------- ---------- -------------------- -------------------- -------------- --------------------
Effect of exchange rates on cash and cash equivalents (208 ) 1,012
-------------------- ---------- -------------------- -------------------- -------------- --------------------
Increase (decrease) in cash and cash equivalents (11,531 ) (17,429 )
Cash and cash equivalents, beginning of period 105,051 100,105
-------------------- ---------- -------------------- -------------------- -------------- --------------------
NOVANTA INC.
Revenue by Reportable Segment
(In thousands of U.S. dollars)
(Unaudited)
Three Months Ended
---------------------------------------------------------------------------------------------------- --------------------
March 29, March 31,
2024 2023
------------------------------ -------------------- ------------------------------ --------------------
Revenue
$ 65,234 $ 69,528
Precision Medicine and Manufacturing
102,452 77,640
Medical Solutions
63,230 71,958
Robotics and Automation
-------------------- ---------- -------------------- -------------------- ---------- --------------------
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands of U.S. dollars)
(Unaudited)
Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Three Months Ended
--------------------------------------------------------------------------------------------------------- --------------------
March 29, March 31,
2024 2023
------------------------------- -------------------- ---------------------------------- --------------------
Precision Medicine and Manufacturing
Gross Profit (GAAP) $ 31,784 $ 34,333
Gross Profit Margin (GAAP) 48.7 % 49.4 %
Amortization of intangible assets 495 570
-------------------- ----------- -------------------- -------------------- -------------- --------------------
Adjusted Gross Profit (Non-GAAP) $ 32,279 $ 34,903
==================== =========== ==================== ==================== ============== ====================
Adjusted Gross Profit Margin (Non-GAAP) 49.5 % 50.2 %
Medical Solutions
Gross Profit (GAAP) $ 39,391 $ 31,886
Gross Profit Margin (GAAP) 38.4 % 41.1 %
Amortization of intangible assets 1,962 1,064
Acquisition fair value adjustments 2,777 --
-------------------- ----------- -------------------- -------------------- -------------- --------------------
Adjusted Gross Profit (Non-GAAP) $ 44,130 $ 32,950
==================== =========== ==================== ==================== ============== ====================
Adjusted Gross Profit Margin (Non-GAAP) 43.1 % 42.4 %
Robotics and Automation
Gross Profit (GAAP) $ 30,549 $ 32,815
Gross Profit Margin (GAAP) 48.3 % 45.6 %
Amortization of intangible assets 1,235 1,388
-------------------- ----------- -------------------- -------------------- -------------- --------------------
Adjusted Gross Profit (Non-GAAP) $ 31,784 $ 34,203
==================== =========== ==================== ==================== ============== ====================
Adjusted Gross Profit Margin (Non-GAAP) 50.3 % 47.5 %
Unallocated Corporate and Shared Services
Gross Profit (GAAP) $ (1,308 ) $ (1,406 )
-------------------- ----------- -------------------- -------------------- -------------- --------------------
Adjusted Gross Profit (Non-GAAP) $ (1,308 ) $ (1,406 )
==================== =========== ==================== ==================== ============== ====================
Novanta Inc.
Gross Profit (GAAP) $ 100,416 $ 97,628
Gross Profit Margin (GAAP) 43.5 % 44.6 %
Amortization of intangible assets 3,692 3,022
Acquisition fair value adjustments 2,777 --
-------------------- ----------- -------------------- -------------------- -------------- --------------------
Adjusted Gross Profit (Non-GAAP) $ 106,885 $ 100,650
==================== =========== ==================== ==================== ============== ====================
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts in thousands except per share amounts)
(Unaudited)
Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Three Months Ended March 29, 2024
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------
Operating Income Operating Margin Income Before Income Taxes Income Tax Provision / (Benefit) Effective Tax Rate Net Income Diluted EPS
------------------------------ -------------------- ------------------------------ -------------------- --------------------------------- -------------------- ------------------------------------ -------------------- ------------------------------ -------------------- ------------------------------ -------------------- ------------------------------ --------------------
GAAP results $ 25,607 11.1 % $ 16,916 $ 2,240 13.2 % $ 14,676 $ 0.41
-------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ------------- -------------------- -------------------- ---------------- -------------------- -------------------- ---------- --------------------
Non-GAAP Adjustments:
9,442 4.1 % 9,442
Amortization of intangible assets
548 0.2 % 548
Restructuring costs
1,735 0.8 % 1,735
Acquisition and related costs
2,777 1.2 % 2,777
Acquisition fair value adjustments
321
Foreign exchange transaction (gains) losses, net
2,963
Tax effect of non-GAAP adjustments
(98 )
Non-GAAP tax adjustments
------------------------------ -------------------- ------------------------------ -------------------- --------------------------------- -------------------- -------------------- ---------------- --------------------
14,502 6.3 % 14,823 2,865 11,958 0.33
Total non-GAAP adjustments
-------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ------------- -------------------- -------------------- ---------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Adjusted results (Non-GAAP) $ 40,109 17.4 % $ 31,739 $ 5,105 16.1 % $ 26,634 $ 0.74
==================== ========== ==================== ==================== ========== ==================== ==================== ============= ==================== ==================== ================ ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ====================
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Amounts in thousands except per share amounts)
(Unaudited)
Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Three Months Ended March 31, 2023
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------
Operating Income Operating Margin Income Before Income Taxes Income Tax Provision / (Benefit) Effective Tax Rate Net Income Diluted EPS
------------------------------ -------------------- ------------------------------ -------------------- --------------------------------- -------------------- ------------------------------------ -------------------- ------------------------------ -------------------- ------------------------------ -------------------- ------------------------------ --------------------
GAAP results $ 26,312 12.0 % $ 19,737 $ 1,472 7.5 % $ 18,265 $ 0.51
-------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ------------- -------------------- -------------------- ---------------- -------------------- -------------------- ---------- --------------------
Non-GAAP Adjustments:
8,111 3.7 % 8,111
Amortization of intangible assets
2,471 1.1 % 2,471
Restructuring costs
5 0.0 % 5
Acquisition and related costs
77
Foreign exchange transaction (gains) losses, net
2,130
Tax effect of non-GAAP adjustments
(3 )
Non-GAAP tax adjustments
------------------------------ -------------------- ------------------------------ -------------------- --------------------------------- -------------------- -------------------- ---------------- --------------------
10,587 4.8 % 10,664 2,127 8,537 0.23
Total non-GAAP adjustments
-------------------- ---------- -------------------- -------------------- ---------- -------------------- -------------------- ------------- -------------------- -------------------- ---------------- -------------------- -------------------- ---------- -------------------- -------------------- ---------- --------------------
Adjusted results (Non-GAAP) $ 36,899 16.8 % $ 30,401 $ 3,599 11.8 % $ 26,802 $ 0.74
==================== ========== ==================== ==================== ========== ==================== ==================== ============= ==================== ==================== ================ ==================== ==================== ========== ==================== ==================== ========== ==================== ==================== ========== ====================
NOVANTA INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands of U.S. dollars)
(Unaudited)
Adjusted EBITDA (Non-GAAP):
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Three Months Ended
---------------------------------------------------------------------------------------------------- --------------------
March 29, March 31,
2024 2023
-------------------------- -------------------- ---------------------------------- --------------------
Net Income (GAAP) $ 14,676 $ 18,265
Net Income Margin 6.4 % 8.3 %
8,254 6,332
Interest (income) expense, net
2,240 1,472
Income tax provision (benefit)
12,929 11,731
Depreciation and amortization
6,077 6,466
Share-based compensation
2,298 2,476
Restructuring, acquisition and related costs
2,777 --
Acquisition fair value adjustments
437 243
Other, net
-------------------- ------ -------------------- -------------------- -------------- --------------------
Adjusted EBITDA (Non-GAAP) $ 49,688 $ 46,985
==================== ====== ==================== ==================== ============== ====================
Organic Revenue Growth (Non-GAAP):
------------------------------------------------------------------------------------------------
Three Months Ended March 29, 2024
Compared to
Three Months Ended March 31, 2023
-------------------------------- --------------------
Reported Revenue Growth/(Decline) (GAAP) 5.4 %
9.7 %
Less: Change attributable to acquisitions
0.1 %
Plus: Change due to foreign currency
-------------------- ------------ --------------------
Net Debt (Non-GAAP):
----------------------------------------------------------------------------------------------------------------------------------------------------------
March 29, December 31,
2024 2023
------------------------------ -------------------- ------------------------------ --------------------
Total Debt (GAAP) $ 513,705 $ 354,372
3,390 3,681
Plus: Deferred financing costs
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Gross Debt 517,095 358,053
(93,520 ) (105,051 )
Less: Cash and cash equivalents
-------------------- ---------- -------------------- -------------------- ---------- --------------------
Free Cash Flow (Non-GAAP):
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Three Months Ended
-------------------------------------------------------------------------------------------- --------------------
March 29, March 31,
2024 2023
-------------------------- -------------------- -------------------------- --------------------
Net Cash Provided by Operating Activities (GAAP) $ 32,829 $ 10,245
(6,415 ) (3,620 )
Less: Purchases of property, plant and equipment
-------------------- ------ -------------------- -------------------- ------ --------------------
Free Cash Flow (Non-GAAP) $ 26,414 $